Lv5
1318 积分 2024-06-07 加入
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
1个月前
已完结
Disease modification in psoriasis through early interleukin 17 inhibitor intervention: A retrospective cohort study
2个月前
已完结
French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025
2个月前
已完结
Identification of key miRNAs and target genes in psoriasis vulgaris and obesity co-morbidity
2个月前
已关闭
French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025
2个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
3个月前
已完结
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
3个月前
已完结
Time to Loss of Disease Control following Guselkumab Withdrawal in Relation to Initial Speed of Response: A post hoc Analysis of the VOYAGE 2 Trial
3个月前
已关闭
Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab
4个月前
已完结
Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy
4个月前
已完结
皖公网安备34019202002308
